Vitality PortfolioMSVDX
Type
Mutual fund
Peer group
Global equity
Net assets
$2.1M
Expense ratio
0.95%
1-year return
+14.9%
3 years, a year
+0.2%
5 years, a year
—
Holdings
33
What it aims to do.
The Vitality Portfolio (the Fund) seeks long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| ARGX Argenx SE | 8.03% |
| LLY Eli Lilly & Co | 7.79% |
| Ascendis Pharma A/S | 5.48% |
| NKTR Nektar Therapeutics | 4.75% |
| TMO Thermo Fisher Scientific Inc | 4.28% |
| ALGN Align Technology Inc | 4.18% |
| ELVN Enliven Therapeutics Inc | 3.90% |
| TXG 10X Genomics Inc | 3.77% |
| JOBY Newamsterdam Pharma Co NV | 3.57% |
| GPCR Structure Therapeutics Inc | 3.36% |
More on MSVDX.
- MSVDX overview
- MSVDX holdings
- MSVDX risk
- MSVDX costs
- MSVDX money in and out
- MSVDX share classes
- Compare MSVDX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.